BIIB : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. Bull of the Day: Quintiles (Q) - Bull of the Day

    March 5, 2014
    Bull of the Day: Quintiles (Q) - Bull of the Day
  3. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  4. A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  5. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  6. Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day

    October 31, 2013
    Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day
  7. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  8. Bull of the Day: Biogen Idec (BIIB) - Bull of the Day

    August 28, 2013
    Bull of the Day: Biogen Idec (BIIB) - Bull of the Day
  9. Can Sanofi Investors Just Blame It On Rio?

    August 6, 2013
    Can Sanofi Investors Just Blame It On Rio? By Stephen D. Simpson, CFA Sanofi (NYSE: SNY) was supposed to be a relatively ...
  10. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  11. Acorda Expands Pipeline - Analyst Blog

    July 11, 2013
    The company acquired Qutenza and NP-1998 from NeurogesX, Inc.
  12. Pharmacyclics Seeks US Approval, Shares Soar - Analyst Blog

    July 11, 2013
    Pharmacyclics is seeking FDA approval for ibrutinib.
  13. Bayer Initiates Phase III Study - Analyst Blog

    July 9, 2013
    Bayer initiated a phase III study on BAY 94-9027 in children with hemophilia A.
  14. Cytokinetics' Update on Study - Analyst Blog

    July 9, 2013
    A programming error was reported by the company's data management vendor.
  15. BioMarin Stays Neutral - Analyst Blog

    July 8, 2013
    We recently maintained our Neutral recommendation on BioMarin Pharma.
  16. pSivida Starts Phase III Study - Analyst Blog

    July 5, 2013
    pSivida Corp. commenced the first of two planned phase III pivotal studies for its micro-insert for the treatment of chronic, ...
  17. FDA Accepts The Medicines Co.'s NDA - Analyst Blog

    July 5, 2013
    A response on the Cangrelor NDA should be out in the second quarter of 2014.
  18. New Data on Biogen's Alprolix - Analyst Blog

    July 3, 2013
    Alprolix is currently under FDA review with a response expected by year end.
  19. Zoetis Looking to Expand - Analyst Blog

    July 3, 2013
    Zoetis intends to expand its manufacturing facility in Lincoln.
  20. Integra Grows European Portfolio - Analyst Blog

    June 27, 2013
    Integra won CE Mark in Europe for its Integra Smart Cervical Solution.
  21. Celgene Inks Oncology Deal - Analyst Blog

    June 27, 2013
    Celgene has joined forces with MorphoSys.
  22. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  23. Isis Pharma Up on Phase II Data - Analyst Blog

    June 25, 2013
    ISIS-APOCIIIRx reduced triglyceride levels and increased good cholesterol levels in type II diabetes patients with high triglycerides.
  24. Positive Data on Infinity's Oncology Candidate - Analyst Blog

    June 25, 2013
    Infinity Pharma announced positive results from a phase I study on its pipeline candidate IPI-145.
  25. SGEN/Takeda Report Data on Adcetris - Analyst Blog

    June 21, 2013
    Seattle Genetics and partner Takeda reported results from a post-hoc analysis evaluating progression-free survival (PFS) ...
  26. Pluristem Updates on IC Study - Analyst Blog

    June 20, 2013
    Pluristem recently announced that it has provided the FDA with additional information regarding the clinical trials for intermittent ...
  27. DaVita and Myriad Join Forces - Analyst Blog

    June 18, 2013
    DaVita HealthCare entered into a strategic liaison with Myriad Genetics.
  28. Perrigo in Expansion Mode - Analyst Blog

    June 18, 2013
    Perrigo has purchased Fera's eye-care portfolio.
  29. Good News for Celgene's Pipeline - Analyst Blog

    June 18, 2013
    Celgene presented positive results on apremilast from a phase II study.
  30. Myriad: End to Legal Battle over Patents - Analyst Blog

    June 17, 2013
    Supreme Court reveals decision on Myriad's patent claims.
  31. Good News for Celgene's Revlimid - Analyst Blog

    June 17, 2013
    The EC approved Revlimid for MDS.
  32. Amgen's Oncology Drug Meets Primary Endpoint - Analyst Blog

    June 13, 2013
    Median progression free survival was better in the trebananib arm compared to the control arm.
  33. Encouraging Data from Bristol-Myers - Analyst Blog

    June 13, 2013
    Bristol-Myers presented encouraging long-term data from a phase IIIb study on Orencia.
  34. Xenon Licenses Isis Drug - Analyst Blog

    June 11, 2013
    With Xenon exercising its option, Isis Pharma is entitled to receive $2 million from Xenon.
  35. 3 Impressive Biotech ETFs Crushing the Market - ETF News And ...

    June 11, 2013
    Rotate into the outperforming biotech sector with these three ETFs.
  36. Royalty Offer Remains Unattractive to Elan - Analyst Blog

    June 10, 2013
    Elan's Board of Directors again rejected Royalty Pharma's offer to acquire all its shares.
  37. Encouraging Data on Alexion's Soliris - Analyst Blog

    June 10, 2013
    Alexion announced that encouraging data on Soliris has been published for treating aHUS patients.
  38. 10 Picks from 2 Strong Sectors

    June 10, 2013
    As we enter the bumpy summer months, large-cap US domestic stocks and health-care names are on Louis Navellier's list, and ...
  39. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  40. Biogen Advances with MS Candidate - Analyst Blog

    January 25, 2013
    Biogen Idec (BIIB) recently announced positive top-line data on its phase III multiple sclerosis candidate, peginterferon ...
  41. Pipeline Update from Alnylam - Analyst Blog

    January 8, 2013
    Alnylam Pharmaceuticals Inc (ALNY) recently announced its goal for the next two years (2013 and 2014) regarding its key "Alnylam ...
  42. CHMP Negative on Isis' Kynamro - Analyst Blog

    December 17, 2012
    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend ...
  43. Alkermes Reverts to Neutral - Analyst Blog

    November 16, 2012
    We are reverting to a Neutral recommendation on Alkermes plc (ALKS) from Outperform as we believe that the stock is fairly ...
  44. Revenues Decline at Alnylam - Analyst Blog

    November 7, 2012
    Alnylam Pharmaceuticals Inc.'s (ALNY) third quarter 2012 net loss of 38 cents per share was wider than the year-ago loss ...
  45. Abbott Among Healthcare's Biggest Movers on October 18, 2012

    October 18, 2012
    The Nasdaq has decreased 0.3%, the S&P 500 has moved little and the Dow has climbed 0.1% so far today. The healthcare sector ...
  46. Isis Pharma Owns 18% of Regulus - Analyst Blog

    October 12, 2012
    Isis Pharmaceuticals, Inc. (ISIS) recently announced that it has invested $3 million in biopharma company Regulus Therapeutics ...
  47. Back to Neutral on Alkermes - Analyst Blog

    September 18, 2012
    We are moving back to a Neutral recommendation on Alkermes plc (ALKS) as we believe the stock is fairly valued at current ...
  48. Biogen Idec and Other Big Movers In Healthcare on September 6, ...

    September 6, 2012
    The morning has been good for the market. The Nasdaq has risen 1.9%; the S&P 500 is up 1.8%; and the Dow has moved up 1.7%. ...
  49. Biogen Inks Deal with Regulus - Analyst Blog

    August 16, 2012
    Regulus Therapeutics Inc. and Biogen Idec (BIIB) recently entered into a deal to identify microRNAs (micro-RiboNucleic Acids) ...
  50. Isis Pharma Stays Neutral - Analyst Blog

    July 11, 2012
    We recently reiterated our Neutral recommendation on Isis Pharmaceuticals (ISIS), which carries a Zacks #3 Rank (short-term ...
  51. New Lease Agreements for Alexandria - Analyst Blog

    June 8, 2012
    Alexandria Real Estate Equities, Inc. (ARE), a real estate investment trust (REIT), recently entered into long-term agreements ...
  52. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  53. 4 Stocks to Buy on Pullbacks

    December 21, 2011
    Ryan Mallory of profiles four specific stocks are good candidates for pullback buys due to their solid long-term ...
  54. 2011's Highest Performing S&P500 stocks

    December 15, 2011
    Check out 2011's highest-performing S&P 500 stocks.
  55. If Pipelines Matter, Novartis Should Be Looking Healthy

    November 30, 2011
    When a company like Novartis comes down the road with a healthy pipeline, the Street seems to respond with worries.
  56. How to Use Technicals to Trade ETFs

    November 7, 2011
    A couple of health-care growth names are performing well after earnings, says Ken Shreve, who also shares his methodology ...
  57. Seattle Genetics – And Now The Hard Bit

    August 23, 2011
    Seattle Genetics got a much-needed FDA approval, but the sales ramp could be challenging for the stock.
  58. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
  59. Finding Value With Icahn

    August 3, 2011
    The holding company appears to have a stable financial situation and with much future upside potential.
  60. 6 High-Flying S&P 500 Stocks

    July 7, 2011
    Check out six S&P 500 stocks that are returning more than 60%.
  61. S&P 500 Winners - Q2 2011

    July 4, 2011
    Learn more about four of the best performing stocks in the Standard and Poor's 500 index during the second quarter of 2011.
  62. April's Top 5 S&P Stocks

    May 3, 2011
    The best performing stocks in the S&P 500 in April 2011 came from the technology, retail and biotechnology sectors.
  63. April's S&P 500 Winners and Losers

    May 2, 2011
    See the best and worst performing S&P 500 stocks from April 2011.
  64. Teva's Rocky Road

    April 26, 2011
    Teva's stock has taken a beating, but the next five years are likely to be tough.
  65. 6 Overbought Stocks To Watch

    April 25, 2011
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  66. Tepid Teva Somewhat Tempting

    February 9, 2011
    Teva's results and outlook will likely leave the stock cooling its heels for a bit in this growth-obsessed market, but patient ...
  67. Icahn's Largest Positions

    January 13, 2011
    We take a peek at some of Icahn Capital LP's top holdings to see what stocks Carl Icahn has selected.
  68. A Look Back At Biotech

    December 28, 2010
    Big biotechs had a mixed year, with concerns about R&D costs and product sales. The stocks may have seen the worst of it, ...
  69. Human Genome Takes A Big Step Forward

    November 17, 2010
    HGSI's prospects get a big boost from a panel approval.
  70. 4 Companies That Should Have Sold Out

    September 9, 2010
    When company management gets unreasonably stubborn and refuses a merger or buyout, shareholders often pay the price.
  71. Another Setback For Roche Is Bad News For ImmunoGen

    August 27, 2010
    Roche suffers another setback to its key cancer franchise, while ImmunoGen faces a major delay in royalty payments.
  72. Big Pharma's Big Problem

    August 16, 2010
    Big Pharma's best patents are expiring, but it may be able to reinvent itself through acquisitions.
  73. Sanofi Has To Do Something

    July 30, 2010
    Sanofi is priced as though it will never grow again - that's usually a good sign of value.
  74. An Unsurprising Increase In Biotech Acquisitions

    July 28, 2010
    The Sanofi/Genzyme combination isn't the only biotech M&A activity on the radar.
  75. Biotech Bargains

    June 17, 2010
    High-growth biotech stocks are now priced like value plays.
  76. 3 Great But Misunderstood Stocks

    May 4, 2010
    Is a lack of understanding of these 3 stocks causing some investors to miss the boat?
  77. Forest Labs Is Green With Cash

    April 16, 2010
    Look beyond the trees and at the entire Forest, and what you see is a great risk reward opportunity.
  78. Earnings Season Pacesetters

    April 12, 2010
    These companies should set the pace for the upcoming earnings season.
  79. Searching For Growth And Value in Biotech

    March 9, 2010
    With health care reform ever present in the news, what are the prospects for biotech firms?
  80. Cash Rich, No Debt Stocks

    February 8, 2010
    Anytime you can find a company with lots of cash and little or no debt, it's worth a closer look.
  81. Forest Labs' Oh-So-Healthy Balance Sheet

    January 26, 2010
    This company has a pristine capital structure and a stockpile of cash, but the best part is that its stock is cheap.
  82. Four Breakout Biotech Stocks

    June 12, 2009
    These four biotech stocks are currently on the upswing.
  83. Is Now The Time To Buy Pharmaceuticals?

    May 5, 2009
    Despite the recession, the pharmaceutical sector continues to show strong year-over-year earnings results and demand worldwide.
  84. Big Pharma's Buying Spree

    April 24, 2009
    A look at recent merger and acquisition activity in the pharmaceutical sector and possible opportunities if the trend continues.
  85. Sigma-Aldrich's New Tech Proves Recession-Proof

    October 29, 2008
    Sigma-Aldrich's Q3 earnings were steady, and with downside protection a major theme in the markets these days, it's hard ...
  86. Leap Of Faith Healing (MEDX, PDLI, AMLN)

    August 8, 2007
    Make the leap with three pharmaceutical companies who require investor courage but could provide a healthy return.
  87. Can Genentech Go Higher?

    April 13, 2006
    A look at the recent quarter of one of the leading biotech companies.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center